The Art Of War Analysis

[Prisc Chandola]

Thisedition of Forum examines the economic and mental health effects of living in the same household as a person with depressive symptoms, as well as the use of financial innovation to meet emission reduction goals.

Professor Wei is the scientific director for the program of quantitative science in pharmaceutical medicine at the Harvard T.H. Chan School of Public Health. He is an expert in biostatistics and in the development of statistical methods for the design and analysis of clinical trials, and has provided deposition and trial testimony in numerous matters regarding the effectiveness of various therapies. Professor Wei also has served as an expert and advisor to a number of pharmaceutical companies and regulatory agencies, including the US Food and Drug Administration (FDA), and has served on a number of FDA and National Institutes of Health committees.

Professor Wei has developed numerous statistical methods that are utilized extensively in practice. He has concentrated his recent research on the development of personalized medicine strategies for diagnostics and treatment selection, and has been intimately involved in advising the pharmaceutical industry on new drug applications.

The author of more than 140 articles in statistical and medical journals, Professor Wei has served on the editorial boards of the Journal of the American Statistical Association and the Journal of Biopharmaceutical Statistics. He is an elected fellow of the Institute of Mathematical Statistics and the American Statistical Association, which honored him with the Mosteller Statistician of the Year award in 2007.

For more than 25 years, Mr. Christensen has worked on high-stakes litigation matters with world-class experts, supporting their testimony at both bench and jury trials. His work has focused on valuation and appraisal matters, private equity disputes, antitrust and consent decree litigations, bankruptcy, and tax and transfer pricing dispute resolutions. Through his extensive experience, he has developed a deep understanding of the high-tech, digital advertising, pharmaceutical, media and entertainment, and finance industries. In addition to his litigation work, Mr. Christensen has also assisted in the preparation of numerous impact studies in the high-tech space on issues such as cloud computing and storage, broadband availability, virtual and augmented reality, artificial intelligence, and the metaverse. His clients have included Meta/Facebook, Google, GSK, AstraZeneca, JAB Holding Company, Bank of America, BNP, and Fidelity. Among his engagements are high-tech antitrust matters, a GSK transfer pricing dispute, the Nortel Networks bankruptcy, Delaware appraisal trial victories involving PetSmart and Panera, and rate-setting trials for BMI. Mr. Christensen is a CFA charterholder.

Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation, damages, and valuation in a variety of health care cases, including cases involving allegations of False Claims Act (FCA), Anti-Kickback Statute (AKS), and Lanham Act violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.

Mr. Gissiner has more than four decades of diversified experience in the retirement plan industry. He is an expert in retirement plan design, compliance, administrative procedures, employee communications and investment education services, and fiduciary responsibility and oversight. Mr. Gissiner has consulted on these and other topics to hundreds of retirement plan sponsors over the course of his career, including various Fortune 500 companies, mutual fund and insurance companies, banks, health care providers, and institutions of higher learning. In addition, he has served as an expert witness in various litigation matters involving defined-contribution retirement plans.

At Orchard Hills Consulting, Mr. Gissiner currently consults on behalf of a number of clients on a wide range of retirement plain issues including (but not limited to) retirement plan administration and compliance consulting, fee benchmarking, assisting plan sponsors and committees in understanding and implementing administrative and recordkeeping fee arrangements, developing service provider requests for proposals, and reviewing modifications to existing plan features and provisions. Earlier in his career, he was a partner in the benefits consulting practice of Coopers & Lybrand. Later, he served as the West Region Managing Partner for retirement plan administrative outsourcing services at PriceWaterhouseCoopers.

Dr. Lehmann specializes in applying microeconomics, econometrics, and statistical methods to complex litigation and government investigations in the areas of antitrust and competition, labor and employment, health care, and commercial damages. She has evaluated market definition, market power, competitive dynamics, class certification, liability, and damages issues in cases involving allegations of price-fixing, monopolization, and other anticompetitive conduct. Dr. Lehmann has extensive experience in labor market antitrust matters involving allegations of no-poach and wage-fixing agreements in a variety of industries. In her work with pharmaceutical and medical device industries, she has analyzed economic, health, and scientific data to assess liability, damages, and claims of causation and harm. She also frequently supports biostatisticians, epidemiologists, scientists, and regulatory experts in evaluating research and development processes and analyzing clinical trial, laboratory testing, registry, medical claims, and adverse events data in product liability litigations and intellectual property disputes. She has authored expert reports and provided testimony in competition, data security breach, labor and employment, and commercial litigation matters.

Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters in all the major international arbitration forums, as well as before the High Court of Justice in London, the Scottish Court of Session, and the UK Competition Appeal Tribunal.

Professor Chevalier is an expert in industrial organization, finance, and competitive business strategy. She has provided expert testimony and been deposed in several major antitrust matters, including State of New York v. Intel Corporation, in which she assessed the business strategies of competitors in the semiconductor industry and evaluated market outcomes. An affiliate with Analysis Group, Professor Chevalier, supported by Analysis Group teams, recently served as an expert in litigation involving online search databases, and in several matters involving entertainment industry issues related to rights, prices, and competition. She has also assisted a number of major technology firms with analyses of competition and antitrust issues. Professor Chevalier's academic research focuses on the economics of electronic commerce, the interaction between firm capital structure and product market competition, and price seasonality and cyclicality. Her research has been featured in Slate magazine and on National Public Radio. Professor Chevalier is also an elected member of the American Academy of Arts and Sciences. She is a former member of the American Economic Association's (AEA) Executive Committee and a former board member of the organization's Committee on the Status of Women in the Economics Profession. In 1999, she won the first biennial Elaine Bennett prize, given by the AEA in recognition of research by a woman in any area of economics. Professor Chevalier is an active author. She has published articles in the American Economic Review; Journal of Industrial Economics; Journal of Business; Quarterly Journal of Economics; Journal of Finance; Journal of Law, Economics, and Organization; and Journal of Political Economy. She is a former coeditor of the Rand Journal of Economics and has served as a coeditor of the American Economic Review, editor of the B.E. Journal of Economic and Policy Analysis, advisory editor of Quantitative Marketing and Economics, and associate editor of numerous journals.

Professor Golder's research focuses on innovation, branding, and global marketing strategy. His research on market entry timing, new products, long-term market leadership, and quality has received widespread acclaim, including the William F. O'Dell Award (Journal of Marketing Research); the Harold H. Maynard Award (Journal of Marketing); the INFORMS Long Term Impact Award (Marketing Science); the Frank M. Bass Award (Marketing Science); the Berry Book Prize (American Marketing Association); and recognition from the Harvard Business Review for co-authoring one of the Top Ten Business Books of the Year (2002). His recent research includes an examination of how economic conditions affect long-term brand leadership persistence and how consumers learn to use multi-feature products like smartphones and websites. He has also recently developed an integrated framework of quality encompassing produced quality, experienced quality, evaluated quality, customer expectations, and customer satisfaction; and explored the historical origins of radical innovations including how they are developed and commercialized.

3a8082e126